Franklin Berger

Franklin Berger

Direttore/Membro del Consiglio presso ATEA PHARMACEUTICALS, INC.

Patrimonio netto: 9 M $ in data 30/09/2026

76 anni
Health Technology
Finance
Consumer Services

Profilo

Mr. Franklin M.
Berger
, CFA MBA, is an Independent Director at Retension Pharmaceuticals, Inc., a Lead Independent Director at Atea Pharmaceuticals, Inc., a Senior Advisor at Qiming US Ventures Management, LLC and a Managing Director at FMB Research.
He is on the Board of Directors at Retension Pharmaceuticals, Inc., Satellos Bioscience, Inc., Atea Pharmaceuticals, Inc. and Walking Fish Therapeutics, Inc. Mr. Berger was previously employed as a Lead Independent Director by Rain Oncology, Inc., a Chairman by Proteostasis Therapeutics, Inc., an Independent Director by ESSA Pharma, Inc., an Independent Director by Atreca, Inc., an Independent Director by Tocagen, Inc., an Independent Director by Immune Design Corp., an Independent Director by BioTime, Inc., an Independent Director by Five Prime Therapeutics, Inc., an Independent Director by BELLUS Health, Inc., a Lead Independent Director by Thallion Pharmaceuticals, Inc., a Senior Manager-Portfolio by NEMO Fund, Inc., a Senior Manager-Investment by Sectoral Asset Management, Inc., an Independent Director by Seattle Genetics, Inc., a Managing Director-Equity Research by JPMorgan Securities, Inc., a Managing Director-Equity Research by Salomon Smith Barney, Inc., a Director-Equity Research by Smith Barney Asset Management, a Managing Director-Equity Research by Josephthal, Lyon & Ross, Inc., and an Advisor by Brookline Capital Acquisition Corp.
He also served on the board at Applied Therapeutics, Inc., Kezar Life Sciences, Inc., Emisphere Technologies, Inc., Isotechnika Pharma, Inc., Isotechnika, Inc., VaxGen, Inc., Alzheon, Inc., Asterias Biotherapeutics, Inc., Aurinia Pharmaceuticals, Inc., Caprion Proteomics, Inc., CellCarta Biosciences, Inc., Episcopal Relief & Development Corp., HealthShares, Inc., iTherX Pharmaceuticals, Inc., The Genetics Co., Inc. and ViroChem Pharma, Inc.

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValutazioneData di valutazione
18/08/2026 690.067 ( 3,25% ) 6 M $ 30/09/2026
18/06/2026 536.097 ( 0,67% ) 3 M $ 30/09/2026
0,27%
13/10/2026 22.517 ( 0,27% ) 237 104 $ 30/09/2026

Posizioni attive di Franklin Berger

SocietàPosizioneInizio
ATEA PHARMACEUTICALS, INC. Direttore/Membro del Consiglio 01/09/2019
SATELLOS BIOSCIENCE INC. Direttore/Membro del Consiglio 29/06/2023
Amministratore Delegato 01/06/2005
Consulente / Consigliere 01/01/2019
Direttore/Membro del Consiglio -

Precedenti posizioni note di Franklin Berger

SocietàPosizioneFine
KEZAR LIFE SCIENCES, INC. Direttore/Membro del Consiglio 11/05/2026
ESSA PHARMA INC. Direttore/Membro del Consiglio 09/10/2025
ATRECA, INC. Direttore/Membro del Consiglio 13/05/2024
RAIN ONCOLOGY INC. Direttore/Membro del Consiglio 25/01/2024
░░░░░░ ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di Franklin Berger

Formazione di Franklin Berger

Esperienze
Posizioni ricoperte

Attive

Inattive

Società nel listino

Aziende private

Relazioni

65

Relazioni di 1° grado

41

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Società collegate

Aziende private41

Health Technology

Health Technology

Distribution Services

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Finance

Finance

Finance

Consumer Services

Health Technology

Miscellaneous

Health Technology

Commercial Services

Health Technology

Health Services

Health Technology

Finance

Health Technology

Commercial Services

NEMO Fund, Inc.

Health Technology

Health Technology

Consumer Services

Health Technology

Miscellaneous

Health Technology

Health Technology

Health Technology

Finance

Health Technology

Finance

Health Technology

  1. Mercati
  2. Insiders
  3. Franklin Berger